New CDK Inhibitors

Catalog No.	Product Name	Information
E6727	GDC-4198	GDC-4198 (Vustanaciclib, RGT-419B, RG6794) is an orally bioavailable, next-generation inhibitor of CDK4/2, which exhibits a therapeutic approach for treating estrogen receptor-positive (ER+/HR+), HER2-negative advanced breast cancers that have progressed on first-line CDK4/6 inhibitor regimens.
E6731	Tacaciclib	Tacaciclib (AUR-102, XL-102) is a specific and orally bioavailable covalent inhibitor of CDK7 with an IC50 of 12 nM, 5 nM and 0.9 nM for 20, 60 and 180 min, respectively. It also induces apoptosis in AML cells via CDK7/c-Myc/p53 axis.
E7630	TG003	TG003 inhibits Clk1/Sty with potency, exhibiting IC50 values of 20 nM for Clk1 and 15 nM for Clk4.
F0536	p14 ARF Antibody [J3P11]	CDKN2A/p14ARF,p14 ARF,p14ARF,p14ARF/CDKN2A
F0549	NFAT1 Antibody [G21N1]	NFAT1,NFATC2,NFATC2/NFAT1
≡ All CDK Inhibitors